Drugs / SAL200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01855048 | Aug 2013 → Feb 2014 | methicillin-resistant staphylococcus aureus infectious disease | Intron Biotechnology, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAL200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01855048 ↗ |
| Known as | N-Rephasin SAL200 | “The purposes of this study are to evaluate the pharmacokinetics, and pharmacodynamics and safety of an experimental intravenous medication, N-Rephasin® SAL200 in healthy male.” NCT01855048 ↗ |
| Modality | Protein / enzyme biologic | “This investigation constitutes the first-in-human phase 1 study of an intravenously administered, phage endolysin-based drug.” PMID 28348152 ↗ May 2017 |
| Route | Intravenous | “continuous intravenous infusion over 60 minutes” NCT01855048 ↗ |